Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies - PubMed (original) (raw)
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies
Jennifer M Timpe et al. Hepatology. 2008 Jan.
Abstract
Hepatitis C virus (HCV) infection of Huh-7.5 hepatoma cells results in focal areas of infection where transmission is potentiated by cell-cell contact. To define route(s) of transmission, HCV was allowed to infect hepatoma cells in the presence or absence of antibodies that neutralize cell-free virus infectivity. Neutralizing antibodies (nAbs) reduced cell-free virus infectivity by >95% and had minimal effect(s) on the frequency of infected cells in the culture. To assess whether cell-cell transfer of viral infectivity occurs, HCV-infected cells were cocultured with fluorescently labeled naïve cells in the presence or absence of nAbs. Enumeration by flow cytometry demonstrated cell-cell transfer of infectivity in the presence or absence of nAbs and immunoglobulins from HCV(+) patients. The host cell molecule CD81 and the tight junction protein Claudin 1 (CLDN1) are critical factors defining HCV entry. Soluble CD81 and anti-CD81 abrogated cell-free infection of Huh-7.5 and partially inhibited cell-cell transfer of infection. CD81-negative HepG2 hepatoma cells were resistant to cell-free virus infection but became infected after coculturing with JFH-infected cells in the presence of nAb, confirming that CD81-independent routes of cell-cell transmission exist. Further experiments with 293T and 293T-CLDN1 targets suggested that cell-cell transmission is dependent on CLDN1 expression.
Conclusion: These data suggest that HCV can transmit in vitro by at least two routes, cell-free virus infection and direct transfer between cells, with the latter offering a novel route for evading nAbs.
Similar articles
- Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF. Krieger SE, et al. Hepatology. 2010 Apr;51(4):1144-57. doi: 10.1002/hep.23445. Hepatology. 2010. PMID: 20069648 - Hepatitis C virus receptor expression in normal and diseased liver tissue.
Reynolds GM, Harris HJ, Jennings A, Hu K, Grove J, Lalor PF, Adams DH, Balfe P, Hübscher SG, McKeating JA. Reynolds GM, et al. Hepatology. 2008 Feb;47(2):418-27. doi: 10.1002/hep.22028. Hepatology. 2008. PMID: 18085708 - Hepatitis C virus entry and neutralization.
Stamataki Z, Grove J, Balfe P, McKeating JA. Stamataki Z, et al. Clin Liver Dis. 2008 Aug;12(3):693-712, x. doi: 10.1016/j.cld.2008.03.008. Clin Liver Dis. 2008. PMID: 18625435 Review. - CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry.
Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, Yuan F, Deng H, Hubscher SG, Han JH, Balfe P, McKeating JA. Harris HJ, et al. J Virol. 2008 May;82(10):5007-20. doi: 10.1128/JVI.02286-07. Epub 2008 Mar 12. J Virol. 2008. PMID: 18337570 Free PMC article. - Hepatitis C virus entry into host cells.
Helle F, Dubuisson J. Helle F, et al. Cell Mol Life Sci. 2008 Jan;65(1):100-12. doi: 10.1007/s00018-007-7291-8. Cell Mol Life Sci. 2008. PMID: 17914604 Free PMC article. Review.
Cited by
- Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M, Nagase S, Shirasago Y, Iida M, Yamashita M, Endo K, Yagi K, Suzuki T, Wakita T, Hanada K, Kuniyasu H, Kondoh M. Fukasawa M, et al. J Virol. 2015 May;89(9):4866-79. doi: 10.1128/JVI.03676-14. Epub 2015 Feb 11. J Virol. 2015. PMID: 25673725 Free PMC article. - Neutralizing antibody response to hepatitis C virus.
Wang Y, Keck ZY, Foung SK. Wang Y, et al. Viruses. 2011 Nov;3(11):2127-45. doi: 10.3390/v3112127. Epub 2011 Nov 2. Viruses. 2011. PMID: 22163337 Free PMC article. Review. - The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection.
Benedicto I, Molina-Jiménez F, Bartosch B, Cosset FL, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fernández A, Aldabe R, López-Cabrera M, Majano PL. Benedicto I, et al. J Virol. 2009 Aug;83(16):8012-20. doi: 10.1128/JVI.00038-09. Epub 2009 Jun 10. J Virol. 2009. PMID: 19515778 Free PMC article. - Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.
Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. Grove J, et al. J Virol. 2008 Dec;82(24):12020-9. doi: 10.1128/JVI.01569-08. Epub 2008 Oct 1. J Virol. 2008. PMID: 18829747 Free PMC article. - Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus.
Webster B, Ott M, Greene WC. Webster B, et al. J Virol. 2013 Dec;87(24):13354-69. doi: 10.1128/JVI.02465-13. Epub 2013 Oct 2. J Virol. 2013. PMID: 24089557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources